Datum Dental, an Israel-based company, was granted regulatory approval in Europe, the U.S., and Canada for its breakthrough mineralized collagen sponge product, OSSIX™ Bone. This new bone graft technology will help regenerate bone and tissue in the oral cavity that was lost as a result of extractions, trauma, or dental disease, via the use of a special biomaterial, which feels like the patient’s own tissue and doesn’t carry the accompanying risks of other bone grafting materials. The material mimics the natural bone formation process in the body, and uniquely facilitates the hardening of tissue into true bone (as demonstrated in human histology). OSSIX™ Bone is based on the building blocks of Datum Dental’s GLYMATRIX® core technology, which already has regulatory approval in Europe, the U.S., APAC, and Canada, and has been featured in more than 110 scientific publications and leading journals. The new technology shows promise in
significantly reducing complications, minimizing the need for repeated procedures and improving the success rate of dental implants.